Open AccessClinical analysis of severe COVID-19 patients
Author(s) -
Hao Wang,
Bin Sun,
Xiayuan Li,
Yun Wang,
Zuodong Yang
Publication year - 2022
Publication title -
technology and health care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.281
H-Index - 44
eISSN - 1878-7401
pISSN - 0928-7329
DOI - 10.3233/thc-228021
Subject(s) - covid-19 , betacoronavirus , medicine , coronavirus infections , pandemic , virology , intensive care medicine , outbreak , disease , infectious disease (medical specialty)
BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospital were collected from January 31 to March 17. RESULTS: The mortality rate of severe patients in our study was 39.3%. There were statistically significant differences in age, admission systolic blood pressure, lymphocyte count, albumin, total bilirubin, and lactate dehydrogenase between the death group and the survival group (P< 0.05). There were statistically significant differences in APACHE II, CURB-65, SOFA, respiratory frequency, systolic pressure, platelet, procalcitonin, albumin, creatinine, creatine kinase isoenzyme, lactate dehydrogenase, chloride ion, prothrombin time, international normalized ratio, arterial partial pressure of oxygen, and FiO2 at ICU between the death group and the survival group (P< 0.05). CONCLUSIONS: Fever and cough are the main symptoms, which is useful for predicting the prognosis to dynamically measure the APACHE II, CURB-65, SOFA, respiratory frequency, lymphocyte count, platelet, lactate dehydrogenase, and coagulation tests. The drugs that protect the liver and heart may improve the survival rate of patients with severe COVID-19.